---
schema_version: "secwatch.filing_event.v1"
accession: "0001802768-26-000002"
form_type: "8-K"
ticker: "RPRX"
cik: "0001802768"
company_name: "Royalty Pharma plc"
filed_at: "2026-02-11T23:59:59+00:00"
generated_at: "2026-05-16T03:21:28.385085+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Royalty Pharma Reports Q4 and Full Year 2025 Results; Portfolio Receipts Up 18% and 16% Respectively

## Summary
- Portfolio Receipts reached $874M in Q4 2025 (up 18%) and $3,254M for FY 2025 (up 16%).
- Net cash from operating activities was $827M in Q4 and $2,490M for FY 2025.
- Deployed $2.6B in capital on royalty transactions in 2025, including nine new therapies.
- Repurchased 37M shares for $1.2B and increased quarterly dividend by 7% to $0.235.
- Provided FY 2026 guidance: Portfolio Receipts expected between $3,275M and $3,425M.

## SEC filing metadata
- accession: 0001802768-26-000002
- form_type: 8-K
- ticker: RPRX
- cik: 0001802768
- company_name: Royalty Pharma plc
- filed_at: 2026-02-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/0001802768-26-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1802768/000180276826000002/rprx-20260211.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001802768-26-000002
- JSON: https://secwatch.observer/filing/0001802768-26-000002.json
- Plain text: https://secwatch.observer/filing/0001802768-26-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.